“The signs are good for biotech deal activity in 2018,” said Chris Stirling, head of KPMG's global life sciences practice. Big companies are under pressure from declining sales of older treatments and many are struggling to find sufficient high-value replacements from within their own laboratories, making ...
Delivered by KPMG Today (@KPMG_TO)
Article continues here
Follow @KPMG_TO on Twitter to get latest updates
